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Hematopoietic stem cells (HSCs) reside pre-
dominantly in the BM and can be purifi  ed 
to near homogeneity based on their c-Kit+, 
Thy1.1low, hematopoietic lineage marker nega-
tive (Lin−), Sca-1+ phenotype; i.e., KTLS cells 
(1, 2). HSCs effi   ciently repopulate the hemato-
poietic system of primary recipients, and puri-
fi  ed donor-derived KTLS cells from engrafted 
mice robustly reconstitute secondary hosts. 
The ability to expand or generate HSCs ex 
vivo would greatly facilitate the development 
of novel therapies for hematopoietic disorders 
for which no current therapy exists, or where 
numbers of available HSCs are insuffi   cient. 
  Although improvement of in vitro HSC expan-
sion or generation of HSCs from embryonic 
stem cells (ESCs) might provide a solution, 
both are at early stages of research. Further-
more, for ESC-derived HSCs to be safe in 
transplantations, they must be free of residual 
teratogenic cells (3–6). Aside from HSCs, the 
BM contains at least one other multipotent 
stem cell population, mesenchymal stem cells. 
The contribution of HSCs is restricted to 
hemato  poietic cells, whereas mesenchymal stem 
cells appear limited to muscle, cartilage, bone, 
and fat diff  erentiation (7, 8). Although rare 
cells have been postulated to contribute to 
both   hematopoietic and nonhematopoietic cells, 
“donor-derived” tissues often express both donor 
and host markers (9–14).
Recently, numerous groups have isolated 
nonhematopoietic cell populations from the 
BM or umbilical cord blood via in vitro  culture, 
which appear able to diff  erentiate into cells 
with mesodermal, endodermal, and ectodermal 
characteristics (15–17). In previously published 
studies, we demonstrated that it was possible 
to isolate a clonal population of cells, named 
Hematopoietic reconstitution by multipotent 
adult progenitor cells: precursors to 
long-term hematopoietic stem cells
Marta Serafi  ni,1 Scott J. Dylla,3 Masayuki Oki,1 Yves Heremans,1 
Jakub Tolar,2 Yuehua Jiang,1 Shannon M. Buckley,1,4 Beatriz Pelacho,1 
Terry C. Burns,1 Sarah Frommer,1 Derrick J. Rossi,3 David Bryder,3 
Angela Panoskaltsis-Mortari,2 Matthew J. O’Shaughnessy,2 
Molly Nelson-Holte,1,4 Gabriel C. Fine,1 Irving L. Weissman,3 
Bruce R. Blazar,2 and Catherine M. Verfaillie1,4
1Stem Cell Institute and 2Cancer Center and Department of Pediatrics, Division of Hematology, Oncology, 
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455
3Department of Pathology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, 
Stanford, CA 94305
4Department of Medicine, Stamcel Instituut Leuven, Katholieke Universiteit Leuven, Leuven 3000, Belgium
For decades, in vitro expansion of transplantable hematopoietic stem cells (HSCs) has been 
an elusive goal. Here, we demonstrate that multipotent adult progenitor cells (MAPCs), 
isolated from green fl  uorescent protein (GFP)-transgenic mice and expanded in vitro for 
> >40–80 population doublings, are capable of multilineage hematopoietic engraftment of 
immunodefi  cient mice. Among MAPC-derived GFP+CD45.2+ cells in the bone marrow of 
engrafted mice, HSCs were present that could radioprotect and reconstitute multilineage 
hematopoiesis in secondary and tertiary recipients, as well as myeloid and lymphoid hema-
topoietic progenitor subsets and functional GFP+ MAPC-derived lymphocytes that were 
functional. Although hematopoietic contribution by MAPCs was comparable to control 
KTLS HSCs, approximately 103-fold more MAPCs were required for effi  cient engraftment. 
Because GFP+ host-derived CD45.1+ cells were not observed, fusion is not likely to account 
for the generation of HSCs by MAPCs.
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multipotent adult progenitor cells (MAPCs), from murine 
BM that contributes to all three germ layers upon   injection 
into blastocysts (18, 19). MAPCs diff  erentiate into various 
lineages in vitro using defi  ned cytokine combinations, and 
when transplanted into sublethally irradiated   nonobese 
  diabetic (NOD)-SCID mice, they contribute at low levels to 
hematopoietic and some endodermal tissues (19). Reyes et al. 
(20) recently reported that MAPC-like cells can be trans-
ferred from donor to host after whole BM transplantation, 
potentially explaining the plasticity of many BM-  derived 
populations (12, 21, 22).
Since the initial description of MAPCs, we improved 
MAPC isolation and expansion conditions (23). MAPC 
clones isolated using improved protocols express Oct4 
(a transcription factor required for undiff  erentiated ESC 
maintenance; reference 24) at levels approaching those of 
ESCs. However, MAPCs do not express two other transcrip-
tion factors known to play a major role in ESC pluripotency, 
Nanog and Sox2 (25–27). These Oct4-expressing MAPCs 
diff  erentiate more robustly in vitro to mesodermal and endo-
dermal cell types as compared with MAPCs described previ-
ously (unpublished data). Here, we demonstrate that MAPC 
populations contribute to hematopoiesis in vivo and may 
precede HSCs in ontogeny given that they generate long-
term repopulating HSCs (LT-HSCs) and the full repertoire 
of hematopoietic progenitors.
RESULTS
Characteristics of Oct4high MAPCs
MAPCs were derived under low oxygen (O2) conditions (23) 
from the BM of two independent C57BL mouse strains that 
express enhanced GFP (eGFP) under control of the β-actin 
promoter. Only MAPC clones that expressed Oct4 at levels 
≥20% of the R1 murine ESC line and stained positive with 
an anti-Oct4 antibody (Fig. S1, available at http://www.jem
.org/cgi/content/full/jem.20061115/DC1) were used for 
subsequent studies. Because Oct4 levels vary upon long-term 
passage, cell aliquots were analyzed for Oct4 mRNA expres-
sion at the time of transplantation (Table S1). Phenotypically, 
MAPCs were CD31, CD44, CD45, CD105, Thy1.1, Sca-1, 
E-cadherin, MHC class I and II, as well as hematopoietic 
lineage marker negative, and expressed low levels of EpCAM 
and high levels of c-Kit, VLA-6, and CD9 (Fig. S2). Further-
more, low O2-derived MAPCs did not express detectable 
transcripts of the hematopoietic-specifi  c transcription factors 
Lmo2, Scl, Gata2, Ikaros, or Pu.1.
Long-term multilineage hematopoietic repopulating activity 
of MAPCs
Initial attempts to transplant 106 MAPCs into lethally irradiated 
C57BL mice failed due to pancytopenia. We next trans-
planted MAPCs into sublethally irradiated NOD-SCID 
mice that also received anti–asialo-GM1 antibodies to deplete 
recipient NK cells (28). 3 wk after transplantation of 0.3–1 × 
106 MAPCs,  5% GFP+CD45.2+ donor cells could be detec-
ted in the blood. The percentage of GFP+ cells increased 
substantially by 6–8 wk and continued to increase until 20 wk after 
transplantation. Engraftment (≥1% GFP+CD45.2+CD45.1− 
cells) was observed in 19/26 and 2/2 mice transplanted with 
MAPC clone DDD and G6, respectively, 3–21 wk after 
transplant (Tables I and S1).
MAPCs transplanted in the 21/28 mice that engrafted 
were <35% hypodiploid or hyperdiploid, and expressed Oct4 
mRNA between 13 and 100% of that observed in mouse 
ESCs (mESCs; Table S1). Of the seven mice that did not 
show hematopoietic engraftment, two animals received cells 
that were 95% aneuploid. Of note, animals transplanted with 
euploid cells or aneuploid cells did not develop tumors with 
posttransplant follow-up of 21 wk. Furthermore, cytogenetic 
analysis on peripheral blood (PB) of MAPC-transplanted 
mice also showed a normal karyotype (Table S3, available at 
http://www.jem.org/cgi/content/full/jem.20061115/DC1). 
Of the remaining fi  ve animals that were not reconstituted, 
three received MAPCs that expressed Oct4 mRNA at levels 
2% of mESC, and two animals showed no engraftment despite 
transplantation with 75 and 90% of euploid cells   expressing 
52 and 55% Oct4 mRNA (vs. mESC), respectively.
Although the degree of hematopoietic contribution from 
MAPCs varied, chimerism of primary recipients was main-
tained until mice were killed as late as 24 wk after transplant. 
GFP+ cells in the BM, spleen, PB, and LNs appropriately 
expressed markers for B lymphocytes, T lymphocytes, or 
myeloid cells (Fig. 1). In the spleen and PB of long-term en-
grafted mice, we also detected GFP+ dendritic cells, NK cells, 
Table I.  Frequency and degree of reconstitution in primary 
MAPC-transplanted mice
Frequency and level of reconstitutiona
0.3–1 × 106 cells 0.3–1 × 105 cells
3–12 wk
12/18 (67%)
(1.0–84.4)b ND
13–21 wk
9/10 (90%)
(8.1–95.3)b
4/11 (36%)
(1.9–2.1)b
Cells
transplantedc 
Transplanted 
mice
Positive 
mice
Positive mice 
(%)
Engraftment 
(%)
1 × 106 19 15 71 82.5 
(69.7–95.3)b
3 × 105 4 4 100 23.0
1 × 105 6 3 50 2.0 
(1.9–2.1)b
3 × 104 5 1 20 1.9
Additional information on engraftment levels and quality control of cells used is 
detailed in Table S1. ND, not done.
aBM of MAPC-reconstituted NOD-SCID mice was analyzed by fl  ow cytometry 3–12 
and 13–21 wk after transplant for the presence of GFP+CD45.1−CD45.2+ donor-
derived cells. Chimerism was determined as presence of ≥1% 
GFP+CD45.1−CD45.2+ donor-derived cells in the BM.
bRange.
c Varying doses of MAPCs were intravenously transplanted into sublethally 
irradiated NOD-SCID mice. 6–21 wk after transplant, BM was examined for 
chimerism. Engraftment was defi  ned as ≥1% GFP+CD45.1−CD45.2+ donor-derived 
cells in the BM. The level of engraftment is the mean of the percentage engraftment 
for each of the dilutions at the latest time point determined (20–21 wk).JEM VOL. 204, January 22, 2007  131
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and megakaryocytes (Fig. S3, available at http://www.jem
.org/cgi/content/full/jem.20061115/DC1). The   majority of 
GFP+ cells in BM obtained between 3 and 10 wk after trans-
plantation were Mac-1+/Gr-1+ double positive, although 
B and T lymphocytes could be detected (Fig. S4). Between 
11 and 21 wk after MAPC infusion, lymphoid repopulation 
increased, thereby confi  rming stable, long-term multilineage 
reconstitution (Fig. S4).
We next evaluated the fraction of animals that engrafted 
with lower doses of MAPCs (3 × 104 to 106 cells/mouse) 
to assess the minimal dose of MAPCs required to establish 
long-term, stable chimerism (Table I). Hematopoietic recon-
stitution of all lineages was observed in one out of fi  ve 
mice injected with 3 × 104 MAPCs and in three out of 
six mice injected with 105 cells, suggesting that the minimal 
dose of MAPCs needed for hematopoietic reconstitution is 
 50,000 cells.
To directly compare MAPC-based contribution to hema-
topoiesis with KTLS HSCs, we co-transplanted 600 KTLS 
cells or 7.5 × 105 MAPCs from β-actin GFP mice with 
0.2–1 × 106 Sca-1–depleted CD45.1+ BM cells in   sublethally 
irradiated NOD-SCID mice. Hematopoietic reconstitution 
by MAPCs was similar to KTLS cells, and the repertoire of 
hematopoietic engraftment by MAPCs versus KTLS cells was 
virtually indistinguishable (Fig. 2).
Several studies have suggested that unexpected contribu-
tion of adult stem cells to tissues other than the lineage of origin 
may be due to fusion of donor cells with host cells (8, 30–32). 
In all mice analyzed, we never detected CD45.1+CD45.2+ 
or CD45.1+GFP+ cells, suggesting that fusion between donor 
(CD45.2+GFP+) MAPCs and recipient (CD45.1+) cells does 
not contribute to hematopoietic reconstitution (Figs. 1 and 2). 
CD45.1+GFPdim cells were present in both MAPC and KTLS 
transplants, but these cells were all Mac1+ and represent host-
derived macrophage engulfment of donor-derived GFP+ 
cells (not depicted).
Self-renewal capacity of MAPC-derived HSCs
Within the GFP+CD45.2+CD45.1− BM cells of primary 
  recipients, we could detect 1–2% ckit+Sca-1+Lin− (KLS) and 
 0.1% ckit+Lin−Sca-1+Flk2− (KLSFlk2−) cells. This sug-
gested in vivo generation of LT-HSCs from MAPCs (Fig. 
3 A; reference 29).
To determine whether functional LT-HSCs were gener-
ated by MAPCs, we evaluated whether MAPC-derived cells 
from primary recipients could stably reconstitute   secondary 
mice. In an initial set of experiments, 106 total BM cells from 
primary recipients of MAPCs or KTLS cells at 16–20 wk 
after transplant were transferred to fi  ve lethally irradiated 
NOD-SCID or C57BL-CD45.1+ mice. Three out of fi  ve 
Figure 1.  Hematopoietic reconstitution from MAPCs grafted in 
NOD-SCID mice. 106 GFP+CD45.2+ MAPCs were transplanted in sub-
lethally irradiated NOD-SCID mice treated with anti–asialo-GM1 antibodies 
4 h before transplantation and on days +11 and +22. Representative 
fl  ow cytometry profi  les of BM, spleen, PB, and LNs of NOD-SCID 
(CD45.1+) mice ≥12 wk after transplant demonstrating multilineage 
(B lymphoid, T lymphoid, and myeloid cells) reconstitution. Contour plots 
shown are after gating on GFP fraction, as indicated.132  HEMATOPOIESIS FROM MULTIPOTENT ADULT PROGENITOR CELLS | Serafi  ni et al.
NOD-SCID and three out of fi  ve C57BL mice that received 
BM from MAPC-engrafted mice, and two out of fi  ve NOD-
SCID and fi  ve out of fi  ve C57BL mice transplanted with 
KTLS progeny survived to week 8 after transplantation. All 
surviving secondary mice had high levels of GFP+CD45.2+ 
multilineage hematopoiesis at 24 wk after transplant (Fig. 3 B). 
Furthermore, similar levels of donor-derived LT-HSCs (KLS 
Flk2−CD34−) and all hematopoietic progenitor populations 
were present in the BM of C57BL secondary recipients of 
KTLS- and MAPC-derived BM cells (Table II and Table S5, 
which is available at http://www.jem.org/cgi/content/full/
jem.20061115/DC1; reference 30). Similar results were 
  observed in a second experiment where total mononuclear 
cells (106 cells/mouse, n = 6) and CD45+ selected cells 
(106 cells/mouse, n = 9) were transplanted from a primary 
MAPC-engrafted recipient, and long-term GFP+CD45.2+ 
hematopoietic reconstitution was detected in secondary 
  recipients (Table III).
To more clearly demonstrate that MAPCs generate 
LT-HSCs, we isolated GFP+KTLS cells from MAPC-engrafted 
animals and transplanted these into secondary recipients. 
Co-transplantation of 200 GFP+KTLS cells with 106 Sca-1–
depleted BM cells into lethally irradiated mice resulted in the 
establishment of long-term GFP+ hematopoiesis in three out of 
four NOD-SCID and four out of four C57BL mice (Table III). 
We further established the generation of functional MAPC-
derived HSCs and their downstream progenitors by demon-
strating that these cells could both radioprotect and establish 
long-term hematopoiesis. To do this, we transplanted 2 × 
103 GFP+ KLS cells without Sca-1–depleted cells. This re-
sulted in robust GFP+CD45.2+ hematopoietic reconstitution 
in two out of three mice, and multilineage reconstitution 
Figure 2.  Hematopoietic reconstitution from KTLS HSCs versus 
MAPCs. 2–3 × 105 Sca-1–depleted, host-derived BM cells were 
co-  transplanted with 600 KTLS or 0.75 × 106 MAPCs from eGFP+CD45.2+ 
donor mice into sublethally irradiated NOD-SCID (N/S) or C57BL-CD45.1+ 
recipients. (A) Mice were evaluated at intermittent time points for PB 
eGFP+CD45.2+ cells. (B) Representative multilineage reconstitution of 
KTLS- versus MAPC-engrafted NOD-SCID mice at week 12.
Table II.  MAPC contribution to hematopoietic stem and 
progenitor populations in secondary recipients
Source of primary BM
Population KTLS MAPCs
LT-HSC 69.6 ± 12% 64.6 ± 27%
CLP 56.9 ± 9% 57.4 ± 18%
CMP 63.5 ± 21% 37.4 ± 27%
GMP 64.3 ± 22% 38.9 ± 30%
MEP 62.5 ± 21% 36.4 ± 27%
0.75 × 106 eGFP MAPCs were transplanted into lethally irradiated NOD-SCID mice 
with 2 × 105 Sca-1–depleted cells of host origin. 20 wk after transplant, 106 BM 
cells were serially transplanted into lethally irradiated C57BL-CD45.1+ hosts. At 
week 24, BM was harvested and assessed for primary donor (eGFP+CD45.2+) 
contribution to LT-HSCs (KLSFlk2−CD34−), common lymphoid progenitors (CLP; 
Lin−ckitlowSca-1lowIL7Rα+Flk2+), common myeloid progenitors (CMP; Lin−ckit+
Sca-1−CD16/32lowCD34+), granulocyte macrophage progenitors (GMP; 
Lin−ckit+Sca-1−CD16/32+CD34+), and megakaryocyte erythrocyte progenitors 
(MEP; Lin−ckit+Sca-1−CD16/32lowCD34−). Data for n ≥ 3 mice per group is shown.
Table III.  Frequency and degree of reconstitution 
in secondary transplants
Cell type Host 
strain
Total MNC 
(1 ×106)
CD45+ 
(1 ×106)
KLS 
(2 × 103)
KTLS 
(2 × 102)
MAPCs
NOD-SCID
a3/3 (100%) 
(13.3–73.7)b 
5/5 (100%) 
(0.4–10)b ND
a3/4 (75%) 
(0.8–16.4)b
C57BL
a3/3 (100%) 
(15.1–90.7)b
a3/4 (75%) 
(3.8–94.8)b
a2/3 (67%) 
(83.0–89.5)b
a4/4 (100%) 
(17.5–30.1)b
KTLS
NOD-SCID
c2/2 (100%) 
(1.7–7.5%)b ND ND ND
C57BL
5/5 (100%) 
(9–77.3%)b ND ND ND
Secondary transplants were performed using cells from GFP+ MAPC- or GFP+ KTLS-
grafted primary mice 16–21 wk after transplantation. Total mononuclear cells 
(MNC) from the BM of primary NOD-SCID or C57BL recipients, and cells enriched 
for CD45+, GFP+Lin−Sca-1+c-kit+ (KLS), or GFP+Lin−Sca-1+c-kit+Thy-1lo (KTLS) 
cells were transplanted intravenously into lethally irradiated NOD-SCID or wild-type 
C57BL-CD45.1+ mice (fi  ve recipient animals for each strain). KTLS populations in 
secondary transfers were co-transplanted with 106 Sca-1–depleted BM cells from 
mice of host background. Animals were killed 15–24 wk after transplantation, 
and engraftment levels were determined in the BM as the presence of 
GFP+CD45.1−CD45.2+ donor-derived cells. The percentage of mice engrafted and 
chimerism ranges are shown. ND, not done.
aWherever the numerator was <5, mice had died due to radiation sickness.
bRange.
cBlood chimerism at week 8. Mice died at week 10 due to illness.JEM VOL. 204, January 22, 2007  133
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that persisted in all secondary recipients until they were killed 
at weeks 15–24 (Table III).
BM obtained 16 wk after transplant from secondary 
  recipients that received 2 × 103 MAPC-derived GFP+ KLS 
cells contained 0.8–1.3% GFP+ KLS cells (not depicted). 
When 106 total BM cells from these secondary recipients 
were transplanted in 10 lethally irradiated tertiary C57BL 
mice, 4–37% GFP+CD45.2+ chimerism was seen in the 
seven tertiary surviving mice 1 mo after transplantation. 
At 3 mo, two out of seven animals showed GFP+CD45.2+ 
chimerism (2.7 and 70%), but engraftment was skewed 
  toward the myeloid lineage. In a separate experiment, of 
the three NOD-SCID mice that received 106 BM cells 
from secondary mice that had received total BM cells from 
primary MAPC- or KTLS-grafted animals, two out of fi  ve 
KTLS- and one out of fi  ve MAPC-derived tertiary reci-
pients remained alive 3 mo after transplant, with multilin-
eage chimerism levels of 8 ± 0.9% and 11.5% in surviving 
mice, respectively.
Immune reconstitution by MAPC-derived 
hematopoietic cells
That MAPCs generate lymphoid cells was fi  rst observed 
  using intravital microscopy, demonstrating obvious GFP fl  uo-
rescence in all lymphoid organs, including the thymus, spleen, 
and LNs (Fig. 4 A). This was confi  rmed by fl  ow cytometry, 
where mature B and T lymphocytes were detected in all 
  organs analyzed (Figs. 1, 4, and S4). In addition, histopathology 
of mesenteric LNs demonstrated that MAPC-derived T and 
B cells can form normal primary follicles (Fig. 4 B).
The thymus of six NOD-SCID mice 6–20 wk after trans-
plant with 106 MAPCs were shown to contain 23 ± 16.5 × 106 
cells (1–50 × 106), of which 73 ± 35.3% (5–99%) were 
GFP+CD45.2+ (Fig. 4 C). GFP+CD45.2+ cells constituted 
major portions of the double-negative, double-positive, and 
CD4 and CD8 single-positive populations (Fig. 4 D). More-
over, >50% of single GFP+CD4 or GFP+CD8 T cells ex-
pressed the TCR-β, as would be anticipated for mature 
thymocytes before emigration into the periphery. All four 
stages of triple-negative thymocytes were also represented 
(Fig. 4 E). Finally, mature T cells were present in inguinal 
LNs (Fig. 1).
To test lymphoid cell function, we examined the in vitro 
response of MAPC-derived CD4/CD8 cells to TCR-CD3/
CD28-mediated signals. The level of [3H]thymidine incor-
poration was similar in splenic T cells from MAPC-engrafted 
versus control GFP-transgenic mice 3–7 d after stimulation 
(Fig. 4 F). Serum of NOD-SCID mice not grafted with 
MAPCs had detectable levels of IgM, but not IgG2. In con-
trast, we detected both IgG2 and IgM in the serum of MAPC-
engrafted mice (n = 6), demonstrating normal B and T cell 
function, as an antibody class switch from IgM to IgG2 had 
occurred (Table IV).
Of note, a single animal developed clinical and pathologi-
cal features indicative of severe chronic graft-versus-host 
  disease (GVHD) 16 wk after transplantation with 0.6 × 106 
MAPCs. Tissue histopathology showed chronic GVHD of 
the skin, along with severely damaged bile ducts in the liver 
and severe lung damage (Fig. 5). In areas of chronic GVHD-
induced injury (not depicted), donor T cells were predomi-
nantly CD3+CD4+, with lesser numbers of CD3+CD8+ 
T cells.
Figure 3.  MAPCs generate KLS Flk2− HSCs and engraft secondary 
recipients. 0.75 × 106 eGFP MAPCs were transplanted into lethally irra-
diated NOD-SCID mice with 2 × 105 Sca-1–depleted cells of host origin. 
20 wk after transplant, 106 BM cells were serially transplanted into 
  lethally irradiated NOD-SCID or C57BL-CD45.1+ hosts. (A) 20 wk after 
transplant, MAPC-engrafted animals were killed and BM was evaluated 
for the presence of eGFP+CD45.2+ hematopoietic stem and progenitor 
cells. (B) PB was obtained periodically to assess primary donor 
(eGFP+CD45.2+) contribution and multilineage (T cell, B cell, and 
myeloid) engraftment.
Table IV.  MAPC-derived B cells undergo antibody 
class switching
Mouse n IgG2 (𝗍g/ml) IgM (𝗍g/ml)
6 652 284
10 139 381
13 NS 190
14 3,671 310
23 189 205
39 60 495
40 18 226
Murine IgM and IgG2 levels were measured by ELISA in the serum of NOD-SCID 
mice 12–21 wk after MAPC transplant. NS, not signifi  cant.134  HEMATOPOIESIS FROM MULTIPOTENT ADULT PROGENITOR CELLS | Serafi  ni et al.
Engraftment in other tissues
We also evaluated engraftment in tissues other than the lym-
phohematopoietic organs with the primary purpose of assess-
ing extrahematopoietic contribution, and secondarily to 
investigate whether microscopic tumors were formed. In all 
sections analyzed, neither microscopic nor macroscopic tumors 
were observed. All GFP+ cells in the tissues analyzed from 
KTLS-transplanted mice were hematopoietic in origin (i.e., 
CD45+), confi  rming no extrahematopoietic contribution by 
HSCs (14). In MAPC-transplanted animals, GFP+ cells were 
readily detectable in the brain, muscle, liver, lung, and gut, but 
the vast majority of these cells were also CD45+. Among the 
GFP+ cells that did not co-label with hematopoietic markers, 
we found no evidence for neural, astrocytic, oligodendrocyte, 
or epithelial diff  erentiation. The nature of these GFP+CD45− 
cells is currently unclear. In three animals, we detected rare 
  individual GFP+ cells within the heart that were striated 
and costained with anti-cardiac troponin-I antibodies (not 
  depicted). The low frequency of this event is consistent with 
cell fusion (9, 14), although these cells were not detectable in 
KTLS-transplanted animals. This would suggest that this con-
tribution is specifi  c to MAPCs, but at the moment we cannot 
speculate on the possible explanation for this phenomenon.
DISCUSSION
In BM, multiple populations of stem and progenitor cells 
  exist with defi  ned potential. The best characterized of these 
is the HSC, which gives rise to all hematopoietic lineages. 
Aside from HSCs, BM also contains other multipotent cells, 
including mesenchymal stem cells. Several recent studies have 
suggested that more primitive cells may exist in the BM or 
umbilical cord blood, with diff  erentiation potential toward 
mesodermal, endodermal, and ectodermal fates, including 
MAPCs (15–19, 31). Each of these populations is purifi  ed 
using in vitro culture techniques, and it remains to be deter-
mined whether they exist in vivo.
We previously demonstrated that clonally derived 
MAPCs contribute to hematopoiesis in a transplant setting 
(19). However, contribution was low (2–8%) and progeny 
were not thoroughly characterized. Here, we show that 
clonally derived MAPCs functionally reconstitute the hemato-
poietic system in vivo and generate HSCs and their progenitor 
cell populations, which robustly contribute to multilineage 
engraftment in primary and secondary irradiated recipients. 
MAPCs alone were not radioprotective, despite the fact that 
the hematopoietic progeny they generated in vivo are radio-
protective. Thus, undiff  erentiated MAPCs cannot be used 
Figure 4.  Functional lymphoid reconstitution in MAPC-engrafted 
animals. Multiparameter analysis was performed to determine the degree 
of lymphohematopoietic engraftment. (A) Intravital microscopy was per-
formed, demonstrating GFP cells in all lymphoid organs, including the 
thymus, spleen, and LNs of a NOD-SCID mouse 13 wk after transplanta-
tion of 106 MAPCs. (B) Hematoxylin and eosin–stained sections of a mes-
enteric LNs harvested from an MAPC-engrafted NOD-SCID mouse, 
demonstrating normal primary lymphoid follicles. (C) Representative pho-
tograph of the thymus from a NOD-SCID mouse 12 wk after transplant 
with fl  ow cytometry, demonstrating >95% GFP+CD45.2+ donor-derived 
cells in the thymus. Representative thymic engraftment by GFP+ MAPC-
derived cells (D) 6 and 12 wk after transplant followed by (E) TCR-β, 
CD44, and CD25 expression profi  les 12 wk after transplant. (F) At 13 wk, 
GFP+ CD4/CD8+ cells were isolated by FACS (95.8% purity) from the 
spleen of an MAPC-engrafted mouse. After stimulation by anti-CD3/
CD28–coated beads, proliferation was assessed by [3H]thymidine 
  incor  poration. Control cells were harvested from the spleen of an MAPC 
donor background CD45.2+GFP+ animal.JEM VOL. 204, January 22, 2007  135
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for transplantation as the sole source of hematopoiesis in 
  lethally irradiated recipients, but can reconstitute long-term 
hematopoiesis. Consistent with the high levels of hemato-
poietic reconstitution by MAPCs, we could detect GFP+ 
cells in all organs analyzed, although most GFP+ cells coex-
pressed CD45. Expression of tissue-specifi  c markers in GFP+ 
cells was only observed in the heart. The low frequency 
of this event, and fusogenic properties of cardiac muscle 
  fi  bers, suggests that this may result from fusion (9, 14). In 
other tissues, rare GFP+ cells that did not co-label with 
  hematopoietic markers also did not stain with antibodies 
against tissue-specifi  c proteins. The nature of these is currently 
under investigation.
Arguably, hematopoietic engraftment cannot be  explained 
by contamination of the graft by HSCs, as MAPCs were 
  expanded for 40–80 population doublings over 3–5 mo in 
vitro. If rare contaminating HSCs were responsible for the 
results observed here, HSC expansion for this period of time 
and to a level of >108–1012-fold would be unprecedented for 
an in vitro culture system. Moreover, MAPCs are derived 
from BM depleted of CD45+ cells, do not express detectable 
CD45, Sca-1, Thy1.1, Mac1, Gr1, CD3, CD4, CD8, B220, 
and Ter119, and do not express HSC-specifi  c transcription 
factors Scl, Lmo2, Gata2, Ikaros, and Pu.1 (quantitative RT-
PCR and gene array analysis [data are available in the GEO 
database under accession numbers GSE5947 and GSE6291]; 
not depicted).
Although several studies initially suggested that adult BM 
stem cells may be capable of acquiring a lineage fate diff  erent 
from the tissue of origin in vivo, several studies have now 
demonstrated that such plasticity is not cell autonomous but 
due to fusion between BM-derived cells and cells in the tar-
get organ (9, 10, 13, 32, 33). Fusion events characteristically 
occur infrequently and do not signifi  cantly contribute to tis-
sue unless the fused cell has a proliferative or survival advan-
tage over nonfused cells (10). Furthermore, fused cells usually 
express some markers of both the host and donor cell. To 
  address whether fusion might explain our observations, we 
used CD45-congenic animals in addition to using donor cells 
universally expressing GFP. In no instance did we observe 
coexpression of CD45.1 with CD45.2 or GFP, except in the 
case of host Mac1+GFPdim cells that represent host macro-
phage engulfment of donor-derived cells (Fig. 2 B), making 
the high level of hematopoietic reconstitution observed after 
MAPC engraftment extremely unlikely due to fusion.
Numerous advances in MAPC isolation, culture, and 
transplantation likely explain the signifi  cantly greater hema-
topoietic reconstitution observed after transplantation in this 
study versus our previous attempts (19). First, we conditioned 
sublethally irradiated NOD-SCID mice with an anti–NK cell 
antibody. Although NOD-SCID mice do not have func-
tional B or T cells, they do have robust NK cell activity, 
which mediates rejection of grafted cells (34). For instance, 
engraftment levels of human SCID-repopulating cells are sig-
nifi   cantly enhanced when human CD34+ cells are trans-
planted in NOD-SCID-IL2Rγc−/− or NOD-SCID-β2M−/− 
mice, or NOD-SCID mice treated with an anti-CD122 
  antibody (34). We recently showed that a substantial fraction 
of murine MAPCs, which are MHC class I low, are rejected 
early after transplantation in NK-competent animals, leading 
to signifi  cantly lower levels of long-term engraftment com-
pared with transplantation into NK-defi  cient animals (28). 
Murine ESC-derived HSCs, which, like MAPCs, are MHC 
class I low, also yield signifi  cantly higher levels of hemato-
poietic engraftment when transplanted into animals that are 
NK defi  cient (4).
Second, MAPCs used in this study were derived using 
improved methodology (23). Compared with previously gen-
erated MAPCs, those derived using 5% O2 express  103-fold 
higher mRNA levels of the ESC-specifi  c transcription factor 
Oct4 (24). We have evidence that the higher level of Oct4 
transcripts is associated with a signifi  cantly broader and more 
robust diff  erentiation ability of MAPCs to several mesodermal 
and endodermal lineages in vitro (unpublished data).
Figure 5.  MAPC-engrafted mouse with chronic GVHD. Intravital 
microscopy and histopathological fi  ndings in one NOD-SCID mouse that 
received 0.6 × 106 MAPCs 16 wk earlier are consistent with the develop-
ment of chronic GVHD. Left panels show the presence of GFP+ cells in the 
GVHD target organs, specifi  cally skin (underlayer), liver, lung, and ileum. 
All intravital images were taken at a zoom factor of 8× and a transfer 
lens of 0.63× with an MZFLIII stereomicroscope (300 millisecond exposure). 
Right panels show the corresponding hematoxylin and eosin stains of 
cryosections taken from the same mouse (bar, 900 μm). The skin shows 
infl  ammation in the dermis and subdermis (black arrow), extensive epi-
dermal hyperplasia (white arrow), and dyskeratosis (asterisk). GVHD score, 
3.5 (0–4 scale). The liver has moderate infl  ammation around the portal 
triads with evidence of bile duct degeneration (black arrow). GVHD score, 
3.0. The lung has peribronchiolar infl  ammation (b, bronchiole) and exten-
sive parenchymal infl  ammation in surrounding areas with organizing 
alveolitis and fi  brosis. GVHD score, 4.0. The ileum shows only mild infl  am-
mation of the lamina propria as is typical for chronic GVHD. GVHD 
score, 0.5.136  HEMATOPOIESIS FROM MULTIPOTENT ADULT PROGENITOR CELLS | Serafi  ni et al.
Not surprisingly, MAPCs were unable to radioprotect 
  lethally irradiated C57BL mice and require co-transplantation 
of Sca-1–depleted BM to prevent death from pancytopenia 
early after transplantation. Because myeloid reconstitution is 
delayed upon transplant of highly purifi  ed HSCs into lethally 
irradiated mice, it is well established that co-transplantation 
of Sca-1–depleted BM cells is needed to transiently pro-
tect animals until mature blood lineages develop (35). The 
notion that MAPCs are unable to radioprotect is consistent 
with the hypothesis that MAPCs precede HSCs during 
  ontogeny, and that commitment to an HSC fate might be 
required before establishing hematopoiesis. The presence of 
KLS Flk2− cells (29), robust engraftment of secondary recip-
ients by MAPC-derived GFP+ KTLS, and radioprotection 
as well as long-term hematopoietic reconstitution by GFP+ 
KLS cells demonstrates that LT-HSCs are, in fact, generated 
by MAPCs.
Compared with freshly isolated KTLS cells, signifi  cantly 
more MAPCs are required to establish hematopoiesis. This 
incongruity likely refl   ects several diff   erences between the 
two cell types. First, it is possible that the effi   ciency of MAPC 
commitment to LT-HSCs is poor. Second, and most nota-
bly, the effi   ciency of MAPC homing and engraftment in BM 
niches is, as yet, unknown. In contrast to KTLS cells, MAPCs, 
aside from Tie2 (36), do not express Cxcr4, Itga4 and Itga5, 
Pecam1, Cd44, or Cd164 (gene array analysis [data are avail-
able in the GEO database under accession numbers GSE5947 
and GSE6291]; not depicted and references 37–41). This 
constellation of chemokine and adhesion receptors is known 
to play a critical role in HSC homing and engraftment, and 
its absence may contribute to the lower engraftment effi   -
ciency of MAPCs versus KTLS cells.
Nevertheless, MAPC-derived progenitors were capable 
of migrating to the thymus, where they underwent typical 
diff  erentiation processes as demonstrated by intravital micro-
scopy, fl   ow cytometry, and tissue immunohistochemistry. 
  Peripheral B and T cell reconstitution of the spleen and LNs 
was intact. Serum Ig levels and IgG2a isotype switching were 
indicative of successful B cell–T cell interactions. In vitro T 
cell responses to CD3 and CD28 signals were intact, and in 
one mouse, donor T cells were suffi   ciently mature to mount 
a chronic GVHD response as confi  rmed by clinicopathologi-
cal analysis and the presence of mature T cells in GVHD tar-
get organs. We do not know the inciting factors for chronic 
GVHD development in this mouse, but possibilities include 
failed thymic negative selection, inadequate peripheral toler-
ance mechanisms, and/or the presence of a pathogen (e.g. 
virus) that might break existing tolerance. Future studies 
measuring in vivo responses to foreign antigens will be 
  required to quantify the extent of functional B and T cell 
  responses. Nonetheless, these data demonstrate the capacity 
of MAPC-derived HSCs to reconstitute irradiated recipients 
with a functional lymphoid system.
In conclusion, we demonstrate that MAPC cultures can 
robustly contribute to hematopoiesis in vivo while generat-
ing functional lymphoid cells and serially transplantable 
HSCs, but they do not generate observable microscopic or 
macroscopic tumors, an important trait when considering 
their therapeutic utility. Because MAPCs can be expanded 
for prolonged periods ex vivo without evidence of senes-
cence and can be easily genetically manipulated, they may 
prove invaluable for the treatment of inherited hematopoi-
etic disorders. Given that MAPCs can diff  erentiate to meso-
derm, endoderm, and ectoderm in vitro (42–44), and to the 
extent that they may be better adapted to do so in vivo given 
the proper environment, MAPCs may greatly facilitate tissue 
repair in vivo through the establishment of hematopoietic 
chimerism as a means to induce transplantation tolerance 
and, therefore, successful transplantation of MAPC-derived 
tissue-committed cells without immune-mediated rejection 
(45, 46).
MATERIALS AND METHODS
Mouse strains. Mice carrying the eGFP gene were provided by M. Okabe 
(Osaka University, Osaka, Japan; C57BL/6TgN(act-EGFP) ObsC14-Yo1-
FM1310) and by I.L. Weissman (C57BL/Ka-CD45.2+-eGFP). Both strains 
use the β-actin promoter to encode for eGFP, and eGFP expression is pres-
ent in >95% of all tissue cells. NOD/LtSz-scid/scid (NOD-SCID) and 
C57BL/6 (CD45.1+) mice were purchased from The Jackson Laboratory. 
Mouse colonies were established at the University of Minnesota for the 
C57BL/Ka-CD45.2+-eGFP, C57BL/6TgN(act-EGFP) ObsC14-Yo1-FM131, 
and NOD-SCID mice. All mice were housed under specifi  c   pathogen-free 
conditions. All protocols involving mice were approved by the Institutional 
Animal Care and Use Committee at the University of   Minnesota and 
Stanford University.
MAPC culture and characterization. MAPCs were isolated from the 
BM of C57BL/6TgN (act-EGFP) ObsC14-Yo1-FM131 mice (clone G6) 
and C57BL/Ka-CD45.2+-eGFP mice (clone DDD), as described previously 
(19, 23). In brief, BM was plated in DMEM/MCDB (Invitrogen) contain-
ing 10 ng/ml EGF (Sigma-Aldrich), PDGF-BB (R&D Systems), and 
LIF (Chemicon International), 2% FCS (Hyclone), 1× selenium-insulin-
  transferrin-ethanolamine, 0.2 mg/ml linoleic acid-bovine serum albumin, 
0.8 mg/ml bovine serum albumin (all from Sigma-Aldrich), 1× chemically 
defi  ned lipid concentrate (Invitrogen), and 1× α-mercaptoethanol (Invitrogen) 
in a humidifi  ed 5% O2 and 6% CO2 incubator. After 4 wk, CD45+ and 
Ter119+ cells were depleted using a MACS separation CS column (Miltenyi 
Biotec) and plated at 10 cells/well. Clones consisting of cells with Oct4 
mRNA levels >20% of mESC (R1 cells, maintained on murine embryonic 
fi  broblasts) were expanded and used for the studies described.
Approximately monthly, MAPCs were analyzed by FACS for cell sur-
face phenotype. Samples were stained with the following fl  uorochrome- 
conjugated antibodies: Sca-1 (E13-161.7); c-kit (2B8); Thy1.1 (OX-7); 
CD44 (IM7); MHC-Ib (H2b, AF6-88.5); MHC-IIb (IAb, AF6-120.1); CD31 
(MEC13.3); CD3 (145-2C11); B220 (RA3-6B2); Mac1 (M1/70); Gr-1 
(8C5); and isotype-PE and APC antibodies. For CD45.2 (104) and CD9 
(KMC8) staining, a biotinylated antibody was used, followed by streptavidin 
and APC. Cells were stained with purifi   ed antibody against E-cadherin 
(ECCD-2; Takara Bio Inc.); EpCAM (G8.8); CD105 (MJ7/18); and CD49f 
(G0H3). An APC-conjugated goat anti–rat IgG F(ab’)2 antibody (Jackson 
ImmunoResearch Laboratories) was used as secondary antibody. All anti-
bodies were from BD Biosciences unless otherwise noted.
Within 1 wk of transplantation, Oct4 transcripts and/or Oct4 protein 
levels were evaluated by quantitative RT-PCR and immunoperoxidase 
staining, respectively (for primers see Table S2). Transcript levels for the 
hematopoietic transcription factors Gata-2, Scl, Lmo2, Pu.1, and Ikaros were 
evaluated by quantitative RT-PCR (for primers see Table S2). MAPCs 
were subjected within 1 wk before transplantation to cytogenetic analysis as 
described previously (23). Results of quantitative RT-PCR for Oct4 and JEM VOL. 204, January 22, 2007  137
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cytogenetic analysis of cells used in the studies described are provided in 
Table S1.
Intermittently, cells were subjected to trilineage (endothelium, hepato-
cyte, and neuroectodermal) diff  erentiation to prove multipotency of the cell 
populations used (19, 42). Diff  erentiation was confi  rmed when transcript 
levels for Sox-1, Otx-1, nestin, and NF200 increased at least 50-fold, reach-
ing levels 50–500% of those measured in embryonic mouse brain RNA (for 
primers see Table S1).
KTLS cell isolation. KTLS (ckit+Sca-1+Thy1.1int/lowLin−) cells were iso-
lated as described previously (1)
MAPC and KTLS cell transplantation. For primary grafts, 6–8-wk-old 
NOD-SCID mice were irradiated with 275 cGy/min at 57 cGy/min. 4 h 
before injection of MAPCs, NOD-SCID mice were treated with an intra-
peritoneal injection of anti-asialo GM1 antibody (20 μL of the stock solu-
tion diluted in 380 μL of 1× PBS; Wako Chemicals). The injection of 
anti-asialo GM1 antibody was also performed after transplantation. Trans-
plantation of MAPCs by tail vein injection occurred 12–24 h after irradiation. 
KTLS cells were transplanted into NOD-SCID mice after irradiation at 
350 cGy. Transplantations of MAPCs or KTLS cells into C57BL-CD45.1+ 
recipients were performed in lethally irradiated (950–1,000 cGy at 57 cGy/
min) animals. KTLS cells, and in some instances MAPCs, were co-injected 
with 2 × 105–106 Sca-1/CD3-depleted BM cells of host origin. Blood was 
obtained at diff  erent times after transplantation to assess engraftment.
Secondary and tertiary transplants were performed using 106 total BM 
cells from primary or secondary recipients, respectively. Secondary trans-
plants were also performed using BM CD45+ cells, 2 × 103 cKit+
Sca-1lowLin−GFP+ cells, or 2 × 102 cKit+Sca-1+Thy1.1int/loLin−GFP+ cells 
isolated by FACS from primary recipients, the latter combined with 106 
Sca-1–depleted BM of host background. Cells were either grafted into 
  sublethally irradiated (275–350 cGy) NOD-SCID mice or lethally irradiated 
(950–1,000 cGy) C57BL-CD45.1+ mice. Blood was obtained at varying 
times after transplant to follow engraftment. 4–26 wk after transplantation, 
animals were killed and analyzed for hematopoietic engraftment as described 
for primary recipients.
Cytogenetic analysis of PB of grafted mice. Cytogenetic analysis was 
performed as recommended by The Jackson Laboratory (http://www.jax
.org/cyto/blood_preps). Three male NOD-SCID mice were transplanted 
with MAPCs purifi  ed from female C57BL/Ka-CD45.2+-eGFP as described 
above. In brief, 0.2 ml of blood was collected from the retroorbital sinus 
of primary recipients into heparinized micro-hematocrit tubes. Cells were 
stimulated by phytohemagglutinine (fi  nal concentration, 7.5 mcg/ml;  Invitrogen) 
and lipopolysaccharide (fi  nal concentration, 50 mcg/ml; Sigma-  Aldrich) 
for 42.5 h, treated with cholchicine, and harvested, and metaphases were 
evaluated according to standard cytogenetic techniques.
Flow cytometric analysis of hematopoietic organs of grafted mice. 
Blood samples were obtained at regular intervals by venipuncture. When the 
mice were killed, hematopoietic organs (BM, PB, spleen, LNs, and thymus) 
were harvested, single cell suspensions were prepared, and red blood cells 
were lysed. Cells were analyzed by fl  ow cytometry for the presence of GFP+ 
donor-derived leukocytes. For FACS analysis, biotinylated or fl  uorochrome-
conjugated mAbs against the following antigens were used: CD45.2, Thy1.1, 
c-kit, Sca-1, CD3, B220, Mac-1, Gr1, MHC-II (clones as described above), 
CD45.1 (A20), CD4 (GK1.5), CD8α (53–6.7), TCRβ (H57-597), TCRγδ 
(GL3), CD19 (1D3), IgM (II/41), CD41 (MWReg30), CD11c (HL3), 
CD25 (PC61), CD44 (IM7), IL-7Rα (A7R34), Flk2 (A2F10), and FcγR 
(CD16/32;2.4G2). GFP+CD45.1−CD45.2+ cells were considered donor 
in origin, and multilineage engraftment was assessed using the markers 
  described above.
Immunohistochemistry for Oct4 on mouse MAPCs and mouse 
ESCs (clone R1). Cells were plated at 100 cells/cm2 and stained with 
goat anti–Oct-3A/4 polyclonal IgG (Santa Cruz Biotechnology, Inc.) or 
incubated with goat gamma globulin (Jackson ImmunoResearch Labora-
tories) as negative control. Biotin SP–conjugated anti–goat IgG (Jackson 
ImmunoResearch Laboratories) was used as secondary antibody. After the 
secondary antibody, cells were incubated for 30 min with ABComplex-
HRP (DakoCytomation) and developed with DAB+ (DakoCytomation) 
for 2–5 min.
Analysis of donor cell engraftment in tissues by intravital micros-
copy. Anesthetized mice (Nembutal) were examined for the presence of 
GFP+ cells by intravital microscopy as described previously using a stereo-
microscope (MZFLIII; Leica) equipped with a GFP2 bandpass fi  lter (Leica) 
and a Retiga Exi camera with Qcapture software (Qimaging). Exposure 
times were kept constant for the diff  erent organs and, for all mice examined, 
for objective comparison of GFP fl  uorescence intensity and any autofl  uores-
cence background (47).
Immunological reconstitution. To assess T cell responses in vitro, 
GFP+CD4+ and GFP+CD8+ cells were isolated from the spleens of an 
  engrafted mouse or a control mouse by FACS. 6 × 104 sorted T cells (ratio 
for CD4/CD8 is 1:1 in MAPC-grafted mouse and control GFP transgenic 
mouse) were cultured in 96-well plates with anti-CD3 mAb plus anti-CD28 
mAb-coated beads (105; provided by C. June and B. Levine, University 
of Pennsylvania, Philadelphia, PA), and pulsed with tritiated thymidine 
(1 μCi/well; GE Healthcare) 16–18 h before harvest and counted in the 
  absence of scintillation fl  uid on a β-plate reader (Packard Instrument Co.). 
Three individual wells were analyzed per data point.
As an indication of T cell responses in vivo, mice were examined for 
evidence of GVHD by clinical characteristics (weight loss and appearance) 
and tissue histopathology using a semiquantitative histopathological scoring 
system as described previously (48).
IgG and IgM serum levels. Ig levels were determined on serial dilutions 
of sera by ELISA at the University of Minnesota Cytokine Reference Labo-
ratory as described previously (48).
Engraftment in organs. Transplanted animals were anesthetized and per-
fused intracardially with 10 ml of 10 mM EDTA/1× PBS, followed by 
10 ml Z-Fix (Anatech). Blood was collected before perfusion with PBS 
and BM between perfusion with PBS and Z-Fix. After systemic perfu-
sion with PBS and Z-Fix, nonhematopoietic organs were removed and 
post-fi  xed in Z-Fix for 24 h at 4°C. Fixed tissues were washed with 1× 
PBS, cryoprotected by overnight incubation in 30% sucrose, quick-frozen 
in optimum cutting temperature compound, and stored at −80°C. 6-μm 
cryosections were thaw-mounted onto glass slides and fi  xed in acetone 
for 5 min. Spleen, LNs, and thymus were immunostained for donor-
derived lymphocytes using anti–CD3-PE, anti–CD4-biotin, rabbit anti–GFP, 
anti–CD19-PE, anti–CD11b-PE, anti–CD11c-biotin, and anti–CD45.2-
biotin (all from BD Biosciences). Biotinylated antibodies were detected with 
streptavidin-Cy5 (BD Biosciences), and rabbit antibodies were detected 
with anti–rabbit Alexa 488 (Invitrogen). Stained tissues were analyzed using 
a confocal microscope (FV500; Olympus) and Fluoview software (version 
3.2; Olympus).
Online supplemental material. The online supplemental material 
contains a more extensive description of the cells transplanted (including 
phenotype, Oct3a transcript and protein level, and cytogenetics) and the 
level of engraftment in each individual animal. Additional information 
is available regarding multilineage reconstitution in the blood, BM, and 
spleen. Online supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20061115/DC1.
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